O'Shaughnessy Asset Management’s Travere Therapeutics TVTX Stock Holding History

O'Shaughnessy Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$337K	Buy	+5,924	New	+$263K	﹤0.01%	1775
2021 Q4	–	Sell	-769	Closed	-$19K	–	2400
2021 Q3	$19K	Sell	769 -2,211	-74%	-$40.6K	﹤0.01%	1967
2021 Q2	$43K	Sell	2,980 -19,240	-87%	-$379K	﹤0.01%	1640
2021 Q1	$554K	Sell	22,220 -2,625	-11%	-$72.5K	0.01%	572
2020 Q4	$677K	Buy	24,845 +6,121	+33%	+$143K	0.02%	436
2020 Q3	$347K	Buy	+18,724	New	+$364K	0.01%	539

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

O'Shaughnessy Asset Management's TVTX Position: Q2 2026 in Review

O'Shaughnessy Asset Management opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 5,924 shares worth $337K. The stake represents ﹤0.01% of the portfolio and ranks #1775 among its holdings. This is a return to the name: O'Shaughnessy Asset Management previously reported a position in TVTX as recently as Q3 2021.

O'Shaughnessy Asset Management first reported a position in TVTX in Q3 2020 and has held it in 6 quarters since. The position peaked at $677K in Q4 2020. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

O'Shaughnessy Asset Management held 5,924 shares of Travere Therapeutics worth $337K as of Q2 2026.
Travere Therapeutics was a new O'Shaughnessy Asset Management position in Q2 2026.
Travere Therapeutics made up ﹤0.01% of O'Shaughnessy Asset Management's portfolio in Q2 2026, its #1775 holding.
O'Shaughnessy Asset Management first reported a position in Travere Therapeutics in Q3 2020 and has held it in 6 quarters since.
O'Shaughnessy Asset Management's Travere Therapeutics position peaked at $677K in Q4 2020.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on O'Shaughnessy Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.